REGENXBIO/$RGNX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About REGENXBIO
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Ticker
$RGNX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
353
ISIN
US75901B1070
Website
REGENXBIO Metrics
BasicAdvanced
$438M
-
-$3.10
1.11
-
Price and volume
Market cap
$438M
Beta
1.11
52-week high
$15.36
52-week low
$5.04
Average daily volume
871K
Financial strength
Current ratio
2.935
Quick ratio
2.821
Long term debt to equity
30.279
Total debt to equity
48.697
Interest coverage (TTM)
-8.17%
Profitability
EBITDA (TTM)
-141.366
Gross margin (TTM)
80.24%
Net profit margin (TTM)
-100.62%
Operating margin (TTM)
-100.41%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
-17.56%
Return on equity (TTM)
-47.44%
Valuation
Price to revenue (TTM)
2.823
Price to book
1.59
Price to tangible book (TTM)
1.59
Price to free cash flow (TTM)
-5.089
Free cash flow yield (TTM)
-19.65%
Free cash flow per share (TTM)
-170.76%
Growth
Revenue change (TTM)
80.70%
Earnings per share change (TTM)
-47.21%
3-year revenue growth (CAGR)
-30.84%
10-year revenue growth (CAGR)
44.95%
3-year earnings per share growth (CAGR)
10.62%
10-year earnings per share growth (CAGR)
0.85%
What the Analysts think about REGENXBIO
Analyst ratings (Buy, Hold, Sell) for REGENXBIO stock.
Bulls say / Bears say
REGENXBIO's RGX-121, targeting Hunter syndrome, is under FDA review with a PDUFA date set for November 9, 2025, potentially positioning it as a new standard of care. (Seeking Alpha)
The company reported new positive functional data from the Phase I/II AFFINITY DUCHENNE® trial of RGX-202, demonstrating consistent evidence of positively changing disease trajectory for Duchenne. (PRNewsWire)
REGENXBIO announced a strategic royalty monetization agreement for up to $250 million, securing $150 million at closing, which extends its cash runway into early 2027. (PRNewsWire)
In Q1 2025, REGENXBIO reported earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.41, representing an earnings surprise of -70.73%. (Nasdaq)
The company exhibits a negative EPS of -$3.09 and a concerning return on equity of -47.44%, highlighting financial challenges typical of clinical-stage biotech firms. (DirectorsTalk Interviews)
REGENXBIO's stock price has exhibited significant volatility, dropping from approximately $28.00 at the beginning of the year to around $23.00 by September 30, 2024, reflecting a decline of about 17.86%. (DCF.fm)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
REGENXBIO Financial Performance
Revenues and expenses
REGENXBIO Earnings Performance
Company profitability
REGENXBIO News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for REGENXBIO stock?
REGENXBIO (RGNX) has a market cap of $438M as of July 18, 2025.
What is the P/E ratio for REGENXBIO stock?
The price to earnings (P/E) ratio for REGENXBIO (RGNX) stock is 0 as of July 18, 2025.
Does REGENXBIO stock pay dividends?
No, REGENXBIO (RGNX) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next REGENXBIO dividend payment date?
REGENXBIO (RGNX) stock does not pay dividends to its shareholders.
What is the beta indicator for REGENXBIO?
REGENXBIO (RGNX) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.